Cell therapy for relapsed or refractory leukemia and myelodysplastic syndromes
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new cell therapy (QH101) for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to standard treatments. It aims to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 years or older.
- You have been diagnosed with AML or MDS that has returned or hasn't responded to standard treatment.
- Your doctor expects you to live at least 3 more months.
- You are generally active (able to care for yourself) and your major organs (heart, lungs, liver, kidneys) are working well enough.
- You agree to use birth control or abstain from sex during the study and for 6 months after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a new treatment using special immune cells (called CAR T cells) that are designed to find and destroy leukemia cells that carry a marker called CD7. It is for people whose T-cell or myeloid leukemia has returned or not responded to standard treatments.
This trial tests a new CAR-T cell therapy, ARD103, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It aims to see if this therapy can help control the disease.
This trial tests an experimental cell therapy called CCTx-001 for people with acute myeloid leukemia that has not responded to standard treatments or has come back. The treatment involves collecting your own immune cells, engineering them, and giving them back to attack the leukemia.
This trial tests a new type of immune cell therapy (called Allo-RevCAR01-T cells) for people with relapsed or hard-to-treat acute myeloid leukemia (AML) that has a marker called CD123. The treatment is given with a separate molecule that helps activate these cells to attack the leukemia. The goal is to see if this approach is safe and can help control the disease.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.